CL2020001252A1 - Métodos de uso y composiciones que contienen dulaglutida. - Google Patents

Métodos de uso y composiciones que contienen dulaglutida.

Info

Publication number
CL2020001252A1
CL2020001252A1 CL2020001252A CL2020001252A CL2020001252A1 CL 2020001252 A1 CL2020001252 A1 CL 2020001252A1 CL 2020001252 A CL2020001252 A CL 2020001252A CL 2020001252 A CL2020001252 A CL 2020001252A CL 2020001252 A1 CL2020001252 A1 CL 2020001252A1
Authority
CL
Chile
Prior art keywords
methods
compositions containing
dulaglutide
containing dulaglutide
dulaglutida
Prior art date
Application number
CL2020001252A
Other languages
English (en)
Spanish (es)
Inventor
David Andrew Cox
Zvonko Milicevic
Lai San Tham
Andrew Gordon Werner
David Bradley Woodward
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020001252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2020001252A1 publication Critical patent/CL2020001252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2020001252A 2017-11-21 2020-05-12 Métodos de uso y composiciones que contienen dulaglutida. CL2020001252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21

Publications (1)

Publication Number Publication Date
CL2020001252A1 true CL2020001252A1 (es) 2020-10-30

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001252A CL2020001252A1 (es) 2017-11-21 2020-05-12 Métodos de uso y composiciones que contienen dulaglutida.

Country Status (21)

Country Link
US (2) US11576950B2 (https=)
EP (1) EP3713593A2 (https=)
JP (3) JP7221956B2 (https=)
KR (2) KR20220146656A (https=)
CN (2) CN120478602A (https=)
AU (2) AU2018372709B2 (https=)
BR (1) BR112020007817A2 (https=)
CL (1) CL2020001252A1 (https=)
CR (1) CR20200202A (https=)
DO (1) DOP2020000104A (https=)
EA (1) EA202090971A1 (https=)
EC (1) ECSP20026436A (https=)
IL (1) IL274563B2 (https=)
JO (1) JOP20200126B1 (https=)
MA (1) MA50798A (https=)
MX (1) MX2020005231A (https=)
PE (1) PE20200847A1 (https=)
PH (1) PH12020550795A1 (https=)
SG (1) SG11202003687RA (https=)
UA (1) UA127588C2 (https=)
WO (1) WO2019103875A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
MX2022009383A (es) * 2020-01-30 2022-11-07 Lilly Co Eli Usos terapéuticos de dulaglutida.
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
CN117915939A (zh) 2021-06-23 2024-04-19 伊莱利利公司 肠降血糖素类似物用于血糖控制和体重管理

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
CN101730523A (zh) * 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド

Also Published As

Publication number Publication date
EP3713593A2 (en) 2020-09-30
UA127588C2 (uk) 2023-10-25
JOP20200126A1 (ar) 2020-05-21
JP7818412B2 (ja) 2026-02-20
CR20200202A (es) 2020-08-20
US11576950B2 (en) 2023-02-14
KR20220146656A (ko) 2022-11-01
IL274563A (en) 2020-06-30
IL274563B1 (en) 2023-08-01
AU2022203372A1 (en) 2022-06-09
SG11202003687RA (en) 2020-06-29
CN111356472A (zh) 2020-06-30
JP7221956B2 (ja) 2023-02-14
ECSP20026436A (es) 2020-06-30
MX2020005231A (es) 2020-08-24
PH12020550795A1 (en) 2021-04-19
IL274563B2 (en) 2023-12-01
KR102589234B1 (ko) 2023-10-16
AU2022203372B2 (en) 2025-04-10
NZ763815A (en) 2023-11-24
US20240189394A1 (en) 2024-06-13
MA50798A (fr) 2020-09-30
JP2024056908A (ja) 2024-04-23
AU2018372709A1 (en) 2020-05-14
CN120478602A (zh) 2025-08-15
BR112020007817A2 (pt) 2020-10-06
JP2021502379A (ja) 2021-01-28
WO2019103875A3 (en) 2019-07-25
US20200330558A1 (en) 2020-10-22
JP2022062153A (ja) 2022-04-19
WO2019103875A2 (en) 2019-05-31
EA202090971A1 (ru) 2020-08-07
DOP2020000104A (es) 2020-08-31
CA3082625A1 (en) 2019-05-31
AU2018372709B2 (en) 2022-04-28
KR20200076705A (ko) 2020-06-29
PE20200847A1 (es) 2020-08-18
JOP20200126B1 (ar) 2024-04-18

Similar Documents

Publication Publication Date Title
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CO2020007244A2 (es) Inhibidores de kras g12c
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2017001994A2 (es) Compuestos activos hacia bromodominios
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
SV2017005471A (es) Derivados de quinazolina utilizados para tratar el vih
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CL2017001046A1 (es) Inhibidoes del bromodominio
CR20160419A (es) Nuevos compuestos biciclicos
DOP2017000298A (es) Reguladores de nrf2
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
CL2018001192A1 (es) Análogos de saponina triterpeno
CL2020001252A1 (es) Métodos de uso y composiciones que contienen dulaglutida.
MX2021006977A (es) Anellosomas y metodos de uso.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t